Portal de recerca
- Inici
- Projectes i Estudis Clínics
- ESTUDIO MULTICÉNTRICO, NO ALEATORIZADO, ABIERTO, PARA VALORAR LA EFICACIA Y LA SEGURIDAD DE LA COMBINACIÓN DE AZACITIDINA Y ERITROPOYETINA BETA EN PACIENTES CON SÍNDROMES MIELODISPLÁSICOS (SMDS) DEPENDIENTES DE TRANSFUSIÓN DE HEMATÍES, DE RIESGO BAJO O INTREMEDIO -1.
ESTUDIO MULTICÉNTRICO, NO ALEATORIZADO, ABIERTO, PARA VALORAR LA EFICACIA Y LA SEGURIDAD DE LA COMBINACIÓN DE AZACITIDINA Y ERITROPOYETINA BETA EN PACIENTES CON SÍNDROMES MIELODISPLÁSICOS (SMDS) DEPENDIENTES DE TRANSFUSIÓN DE HEMATÍES, DE RIESGO BAJO O INTREMEDIO -1.
Dades bàsiques
- Protocol:
- SIMIDIS
- EURDRACT:
- 2007-000972-18
- NCT:
- Centre:
- Any inici:
- Any de finalització:
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)
Wei, AH; (...); DiNardo, CD
Article. 10.1038/s41408-021-00555-8. 2021
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia
Sweet, Kendra; (...); Montesinos, Pau
Article. 10.1080/10428194.2021.1950706. 2021
A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)
Zabaleta, Aintzane; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-184797. 2023
A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML
Perez Miguez, Carlos; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2024-201407. 2024
A High Percentage of DNAM-1+and Low Percentage of Tactile plus NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial
Bergua Burgues, Juan Miguel; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-189676. 2023
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 (Lacutoclax) As Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Burgues, Juan Miguel Bergua; (...); Curran, Emily K.
Meeting Abstract. 10.1182/blood-2024-208792. 2024
A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.
Daver, Naval Guastad; (...); Sallman, David Andrew
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS6585. 2024
A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML)
Daver, Naval Guastad; (...); Sweet, Kendra Lynn
Meeting Abstract. 2023
A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia
Daver, Naval; (...); Sweet, Kendra
Meeting Abstract. 10.1182/blood-2021-146585. 2021
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
Rodríguez-Arbolí E; (...); Montesinos P
Article. 10.1002/cncr.35618. 2024
A PHASE 3 STUDY OF ENASIDENIB (ENA) VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH LATE-STAGE MUTANT-IDH2 (MIDH2) RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)
Papayannidis, C.; (...); de Botton, S.
Meeting Abstract. 2021
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia.
Montesinos, Pau; (...); McMullin, Mary Frances
Article. 10.1007/s00280-023-04516-9. 2023
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS
Oster, HS; (...); Mittelman, M
Article. 10.1182/bloodadvances.2020004055. 2021
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.
Zeidner JF; (...); Douglas Smith B
Letter. 10.1038/s41408-021-00568-3. 2021
A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy
Jamy, Omer Hassan; (...); Cicic, Dragan
Meeting Abstract. 2023
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.
Berard, Emilie; (...); Recher, Christian
Article. 10.1038/s41408-022-00700-x. 2022
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study
Maggioni, Giulia; (...); Della Porta, Matteo G.
Article. 10.1016/S2352-3026(22)00323-4. 2023
A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms
Liquori, A; (...); Cervera, J
Article. 10.3390/cancers13081947. 2021
A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
Kuendgen, A.; (...); Sanz, G.
Meeting Abstract. 10.1016/j.leukres.2023.107226. 2023
A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Pemmaraju, Naveen; (...); Daver, Naval
Meeting Abstract. 10.1182/blood-2021-146681. 2021
A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?
Solana-Altabella A; (...); Montesinos P
Article. 10.1007/s00277-024-05891-w. 2024
Aberrant Alternative Splicing in U2af1/Tet2 Double Mutant Mice Contributes to Major Hematological Phenotypes
Martínez-Valiente C; (...); Sanjuan-Pla A
Article. 10.3390/ijms22136963. 2021
ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS - AN ANALYSIS OF THE IWG-PM DATABASE
Pfeilstoecker, M.; (...); Greenberg, P.
Meeting Abstract. 10.1016/j.leukres.2023.107230. 2023
Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML
Erba, Harry; (...); Fathi, Amir
Meeting Abstract. 2023
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.
Hernandez-Boluda, Juan-Carlos; (...); PETHEMA group
Article. 10.1016/j.leukres.2022.106821. 2022
Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene (vol 12, 624, 2020)
Article. 10.3390/cancers13143440. 2021
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review
Review. 10.1177/20406207211038181. 2021
Adverse prognostic impact of complex karyotype (>= 3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)
Genesca, E; (...); Ribera, JM
Article. 10.1016/j.leukres.2021.106612. 2021
AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib plus Azacitidine Versus Placebo plus Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Montesinos, Pau; (...); Doehner, Hartmut
Meeting Abstract. 10.1182/blood-2021-147805. 2021
Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT.
Montoro J; (...); Peffault de Latour R
Article. 10.1182/blood.2024024173. 2024
Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.
Chihara D; (...); Yakoub-Agha I
Letter. 10.3324/haematol.2022.281754. 2023
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Maffini, Enrico; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02027-y. 2023
Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT.
Esteve, Jordi; (...); Ciceri, Fabio
Article. 10.1002/ajh.27647. 2025
Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia
Dholaria, B; (...); Mohty, M
Article. 10.1186/s13045-021-01086-2. 2021
Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
Berning, Philipp; (...); Glass, Bertram
Meeting Abstract. 10.1182/blood-2022-164637. 2022
Allogeneic hematopoietic stem cell transplantation achieves long-term survival in Natural killer/T-cell lymphoma in the era of Asparaginase-based Chemotherapy
Berning, P.; (...); Glass, B.
Meeting Abstract. 2023
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis.
Berning, Philipp; (...); Glass, Bertram
Article. 10.1038/s41375-023-01924-x. 2023
Allogeneic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia (AML) in Second Complete Remission (CR2) Transplanted from Unrelated Donors with Post Transplant Cyclophosphamide (PTCy). a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-144894. 2021
Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-01940-6. 2023
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT.
Al Hamed R; (...); Mohty M
Article. 10.1038/s41409-024-02373-5. 2024
ALLOGENEIC TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED FEATURES AS PER THE INTERNATIONAL CONSENSUS CLASSIFICATION (ICC) 2022: FROM THE ALWP OF THE EBMT
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 2024
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
Stahl, Maximilian; (...); Zeidan, Amer M.
Letter. 10.1182/bloodadvances.2022008747. 2023
AN INTERIM ANALYSIS OF FOVOCIP: A MULTICENTER RANDOMIZED TRIAL OF FOSFOMYCIN VERSUS CIPROFLOXACIN FOR FEBRILE NEUTROPENIA PREVENTION IN HEMATOLOGIC PATIENTS
Fernandez Moreno, Ahinoa; (...); Bernal, Teresa
Meeting Abstract. 2024
An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.
Fiedler, Walter; (...); Blum, William
Article. 10.3324/haematol.2022.281128. 2022
Anti-CD19 CAR-T cell therapy in elderly patients: multicentric real-world experience from GETH-TC/GELTAMO.
Bailen, Rebeca; (...); Kwon, Mi
Article. 10.1016/j.jtct.2024.06.022. 2024
ANTITHYMOCYTE GLOBULIN - OR ALEMTUZUMAB-BASED GVHD PROPHYLAXIS IN REDUCED- INTENSITY CONDITIONING ALLO-HCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CR1: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY
Bug, Gesine; (...); Mohty, Mohamad
Meeting Abstract. 2023
Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A
Venditti, Adriano; (...); Pullarkat, Vinod A.
Meeting Abstract. 10.1182/blood-2022-158500. 2022
Association of Unbalanced Translocation der(1;7) with Germline GATA2 Mutations.
Kozyra, EJ; (...); Wlodarski, MW
Article. 10.1182/blood.2021012781. 2021
Atypical B-Cell Acute Lymphoblastic Leukemia with iAMP21 in the Context of Constitutional Ring Chromosome 21: A Case Report and Review of the Genetic Insights.
Gil, Jose Vicente; (...); Llop, Marta
Article. 10.3390/ijms26010357. 2025
Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy.
Wei, AH; (...); DiNardo, CD
Article. 10.1038/s41408-021-00565-6. 2021
Autologous or allogeneic hematopoietic stem cell transplantation as front-line treatment for adult secondary acute myeloid leukemia patients: the PETHEMA registry experience.
Serrano, Josefina; (...); Montesinos, Pau
Article. 10.1016/j.jtct.2025.02.011. 2025
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Kwon M; (...); Barba P
Article. 10.3324/haematol.2022.280805. 2023
Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain
Kwon, Mi; (...); Barba, Pere
Meeting Abstract. 10.1182/blood-2021-147369. 2021
Azacitidine or Decitabine Monotherapy for the Treatment of AML: A Comparative Systematic Review and Meta-Analysis
Saiz-Rodriguez, M; (...); Montesinos, P
Meeting Abstract. 2021
AZACITIDINE VS. DECITABIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA RE-DIAGNOSED: RESULTS OF THE PETHEMA AML REGISTER
Jorge, Labrador; (...); Pau, Montesinos
Meeting Abstract. 2021
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14092342. 2022
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
Bastos-Oreiro, Mariana; (...); Garcia-Sancho, Alejandro Martin
Article. 10.3389/fimmu.2022.855730. 2022
Biallelic TET2 mutation sensitizes to 5'-azacitidine in acute myeloid leukemia.
Stölzel F; (...); Allan, James M.
Article. 10.1172/jci.insight.150368. 2022
Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC
Pena, Marta; (...); Balari, Anna Maria Sureda
Meeting Abstract. 10.1182/blood-2023-181815. 2023
Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients
Platzbecker, Uwe; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2022-160127. 2022
Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Daver, Naval; (...); Sweet, Kendra
Meeting Abstract. 10.1182/blood-2022-158030. 2022
Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in HematologY Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools.
Cerisoli, Francesco; (...); Hernandez Rivas, Jesus Maria
Article. 10.1016/j.jval.2022.04.1729. 2022
CART-AI-Radiomics: Survival and Neurotoxicity Prediction in B-Cell Lymphoma Patients Treated with CAR-T Cells through an Imaging Features-Based Model
Ferrer Lores, Blanca; (...); Jose Terol, Maria
Meeting Abstract. 10.1182/blood-2023-185088. 2023
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
Madry, Krzysztof; (...); Smith, Alex
Article. 10.1111/bjh.18542. 2022
Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia
Morote-Faubel, Mireya; (...); Cervera, Jose
Meeting Abstract. 10.1182/blood-2023-177571. 2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M; (...); Zeidan AM
Article. 10.1016/j.blre.2023.101128. 2023
Clinical and Biological Characterization of Low Risk MDS Patients According to Ring Sideroblasts (RS). Comparison between the 3 Subgroups in WHO2017 Classification. Study from the Spanish MDS Registry
Lopez Cadenas, Felix; (...); Diez-Campelo, Maria
Meeting Abstract. 10.1182/blood-2021-152678. 2021
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.
Tentori CA; (...); Della Porta MG
Article. 10.1200/JCO.23.02175. 2024
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (vol 100, pg 1181, 2021)
Heuser, Michael; (...); Cortes, Jorge E.
Article. 10.1007/s00277-021-04545-5. 2021
Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group
Romero, Alejandra; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-163869. 2022
Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)
Vicente, Navarro; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-190296. 2023
Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes
Riva, Elena; (...); Della Porta, Matteo G.
Meeting Abstract. 10.1182/blood-2022-166050. 2022
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.
Bernal, Teresa; (...); Montesinos, Pau
Article. 10.1002/cam4.6120. 2023
Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib
Perl, AE; (...); Tiu, RV
Meeting Abstract. 2021
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Perl, Alexander E.; (...); Altman, Jessica K.
Article. 10.1038/s41408-022-00677-7. 2022
Clinical Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study
Sanz, Jaime; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-147296. 2021
CLINICAL-BIOLOGICAL AND PROGNOSTIC CHARACTERISTICS OF LOW RISK SMD WITHOUT RING SIDEROBLASTS AND COMPARISON WITH ITS COUNTERPART WITH RING SIDEROBLASTS
Cadenas Felix, Lopez; (...); Ferreiras David, Valcarcel
Meeting Abstract. 2021
Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)
Colmenares, Rafael; (...); Montesinos, Pau
Meeting Abstract. 2023
CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.
Article. 10.1016/j.jtct.2024.01.082. 2024
CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice
Chiusolo, Patrizia; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-182831. 2023
Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic.
De La Puerta R; (...); Piñana JL
Article. 10.1038/s41409-021-01319-5. 2021
Comparative Study of Treosulfan Plus Fludarabine (FT14) with Busulfan Plus Fludarabine (FB4) for Acute Myeloid Leukemia in First or Second Complete Remission: An Analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)
Gavriilaki, Eleni; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-146303. 2021
Comparing Older Matched Related to Younger Matched Unrelated Donors in Acute Myeloid Leukemia in Remission Using Post-Transplant Cyclophosphamide
Piemontese, Simona; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-182923. 2023
COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
Kuendgen, A.; (...); Sanz, G.
Meeting Abstract. 2021
Comparison of Haploidentical Peripheral Blood Cell Transplantation Using Post-Transplant Cyclophosphamide With Double Cord Blood Transplantation in Adults With Acute Leukemia
Ruggeri, A; (...); Mohty, M
Meeting Abstract. 2021
Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT.
Ruggeri, Annalisa; (...); Mohty, Mohamad
Article. 10.1016/j.jtct.2022.07.006. 2022
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Sargas, Claudia; (...); Montesinos, Pau
Article. 10.1038/s41408-023-00835-5. 2023
COMPARISON OF THREE PANELS OF NGS APPLICATION IN ONCOHEMATOLOGY TO DISCARD SOMATIC AND/OR GERMINAL VARIANTS
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
Comprehensive detection of CRLF2 alterations in acute lymphoblastic leukemia: a rapid and accurate novel approach.
Gil, Jose Vicente; (...); Barragan, Eva
Article. 10.3389/fmolb.2024.1362081. 2024
CONCORDANCE STUDY ON THE CATEGORIZATION OF NON-CANONICAL VARIANTS OF JAK2 GENE
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
Concurrent Zrsr2 mutation and Tet2 loss promote myelodysplastic neoplasm in mice
Garcia-Ruiz C; (...); Sanjuan-Pla A
Article. 10.1038/s41375-022-01674-2. 2022
CONDITIONING INTENSITY IN STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 2024
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes.
Zeidan, Amer M.; (...); Fenaux, Pierre
Article. 10.1182/blood.2022018604. 2023
Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS).
Aakash, Fnu; (...); Loghavi, Sanam
Article. 10.1016/j.modpat.2024.100615. 2024
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.
Gonzalez-Gil C; (...); Genesca E
Article. 10.3324/haematol.2024.285416. 2024
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
Boluda, Blanca; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-160136. 2022
CO-OCCURRENCE PROFILES OF GERMLINE AND ACQUIRED VARIANTS IN MYELODYSPLASTIC SYNDROMES IN YOUNG ADULTS WITHOUT PRIOR ORGAN DYSFUNCTION
Hua, Chen-Liang Tzu; (...); Andres, Jerez
Meeting Abstract. 2021
Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan.
Watanabe, Mizuki; (...); Gluckman, Eliane
Article. 10.1182/bloodadvances.2023010598. 2024
CORD BLOOD TRANSPLANTATION FOR AML: COMPARABLE LFS IN PATIENTS WITH DE NOVO VERSUS SECONDARY AML
Baron, Frederic; (...); Ciceri, Fabio
Meeting Abstract. 2023
Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
Baron, Frederic; (...); Ciceri, Fabio
Article. 10.1111/bjh.19130. 2023
Correction to: Spanish registry of hemoglobinopathies and rare anemias (REHem- AR): demographics, complications, and management of patients with ß-thalassemia.
Bardón-Cancho EJ; (...); Cela E
Correction. 10.1007/s00277-024-05838-1. 2024
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Mussetti, Alberto; (...); Sureda, Anna
Correction. 10.1038/s41409-023-01967-9. 2023
Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia (vol 13, 1302993, 2023)
Orgueira, Adrian Mosquera; (...); Encinas, Manuel Mateo Perez
Correction. 10.3389/fonc.2023.1302993. 2023
Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain
Mareque, M; (...); Sierra, J
Article. 10.2147/CEOR.S302097. 2021
Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study
Lancet, Jeffrey; (...); Carraway, Hetty E.
Meeting Abstract. 10.1182/blood-2023-173149. 2023
COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Rosenberg, Aaron; (...); Khouri, Jack
Meeting Abstract. 2023
Cryopreservation of Allogeneic Hematopoietic Progenitor Cells in The Current SARS-Cov-2 Pandemic: Experience of A Single Centre
Moreno, D; (...); Carpio, N
Meeting Abstract. 2021
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).
Bewersdorf, Jan Philipp; (...); Zeidan, Amer M.
Article. 10.1016/j.blre.2023.101072. 2023
Current Results on Overall Survival with oral Azacitidine Therapy in Patients with acute Myeloid Leukemia in first Remission after intensive Chemotherapy in the Phase 3 QUAZAR Study
Pfeilstoecker, M.; (...); Roboz, G. J.
Meeting Abstract. 2022
Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alotaibi, Shaykhah; (...); Aljurf, Mahmoud
Article. 10.1016/j.clml.2022.02.008. 2022
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Article. 10.3390/cancers15113039. 2023
Cytomegalovirus DNAemia in hematological patients undergoing CD19-directed CAR-T cell therapy: should it be systematically monitored?
Solano de la Asuncion, Carlos; (...); Navarro, David
Letter. 10.1016/j.cmi.2023.05.010. 2023
Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib plus azacitidine or placebo plus azacitidine.
Schuh, Andre C.; (...); Montesinos, Pau
Meeting Abstract. 2022
Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants.
Cicconi, L; (...); Abla, O
Article. 10.1038/s41408-021-00561-w. 2021
Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4
Kayser, Sabine; (...); Schlenk, Richard F.
Meeting Abstract. 10.1182/blood-2021-150281. 2021
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Kayser, Sabine; (...); Schlenk, Richard F.
Meeting Abstract. 10.3324/haematol.2022.281137. 2022
Characteristics and outcome of patients with core binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.
Kayser S; (...); Levis MJ
Article. 10.3324/haematol.2021.278645. 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.
Martinez-Cuadron, David; (...); On Behalf Of The Pethema Group
Article. 10.3390/cancers14112817. 2022
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
Palanques-Pastor, Tomas; (...); Montesinos, Pau
Article. 10.1080/10428194.2021.1948031. 2021
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.
Vincent, Laure; (...); Beksac, Meral
Letter. 10.1038/s41409-021-01560-y. 2022
Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)
Gonzalez, Carmen; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-180646. 2023
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Komrokji RS; (...); Della Porta MG
Article. 10.1016/S2352-3026(24)00251-5. 2024
Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial.
Montesinos, Pau, Sossa-Melo, Claudia
Article. 10.1016/S2352-3026(23)00308-3. 2023
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.
Stojkov I; (...); Siebert U
Article. 10.1182/bloodadvances.2022008360. 2023
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.
Montesinos P; (...); DiNardo CD
Article. 10.1182/bloodadvances.2023011914. 2024
Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)
Santini, Valeria; (...); Zeidan, Amer M.
Meeting Abstract. 10.1182/blood-2022-160282. 2022
Disseminated toxoplasma infection after hematopoietic stem cell transplantation with myositis and encephalitis.
Asensi Cantó P; (...); Guerreiro M
Article. 10.1111/tid.14067. 2023
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Suárez EU; (...); Montesinos P
Article. 10.1007/s00277-024-05840-7. 2024
Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database
Azibeiro Melchor, Raul; (...); Ossenkoppele, Gert J.
Meeting Abstract. 10.1182/blood-2021-150766. 2021
Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Hutchings, Martin; (...); Subklewe, Marion
Meeting Abstract. 10.1182/blood-2023-173302. 2023
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.
Solana-Altabella, Antonio; (...); Montesinos, Pau
Article. 10.1080/17512433.2023.2174523. 2023
Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories
Pfeilstocker, Michael; (...); Greenberg, Peter L.
Meeting Abstract. 10.1182/blood-2022-158671. 2022
Early-Onset Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) without SF3B1 Mutations in Adults: Enrichment with Germline Variants in Genes Responsible for Congenital Sideroblastic Anemias
Jauregui, Sandra Novoa; (...); Jerez, Andres
Meeting Abstract. 10.1182/blood-2023-185836. 2023
Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.
De Botton, Stephane; (...); Fenaux, Pierre
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7006. 2021
EFFECTIVENESS AND TOXICITY OF THE USE OF INOTUZUMAB (INO) IN PATIENTS WITH RESISTANT OR RECALLING (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (LAL). STUDY OF PATIENTS INCLUDED IN INO'S EXPANDED USE PROGRAM
Ribera Santasusana, J. M.; (...); Valero, M.
Meeting Abstract. 2021
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
Zeiser R; (...); Chen YB
Article. 10.1016/S2352-3026(21)00367-7. 2022
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301) : a randomised, multicentre, double-blind, phase 3 trial
Zeiser, Robert; (...); Chen, Yi-Bin
Article. 10.1016/S2352-3026(21)00367-7. 2022
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
Solana-Altabella, Antonio; (...); Montesinos, Pau
Article. 10.1080/14728214.2021.2009800. 2022
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
DiNardo CD; (...); Döhner H
Article. 10.1016/S1470-2045(21)00494-0. 2021
Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.
de Botton, Stephane; (...); DiNardo, Courtney D.
Article. 10.1182/blood.2021014901. 2022
Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study
Montesinos, Pau; (...); Recher, Christian
Meeting Abstract. 10.1182/blood-2024-194356. 2024
Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Meeting Abstract. 10.1182/blood-2023-180691. 2023
Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)
Segui, Ines Gomez; (...); Garma, Julio Del Rio
Meeting Abstract. 2024
Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency.
Marin-Bejar, Oskar; (...); Giorgetti, Alessandra
Article. 10.3324/haematol.2022.282305. 2023
ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder
Carrillo-Tornel, Salvador; (...); Jerez, Andres
Meeting Abstract. 10.1182/blood-2022-168759. 2022
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Sanz, Jaime; (...); Ciceri, Fabio
Article. 10.1038/s41409-023-02075-4. 2023
Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
Lopez Cadenas, Felix; (...); Diez-Campelo, Maria
Meeting Abstract. 10.1182/blood-2022-168718. 2022
Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia
Mosquera Orgueira, Adrian; (...); Perez Encinas, Manuel Mateo
Article. 10.3389/fonc.2022.968340. 2022
Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
Labrador, Jorge; (...); Manuel Alonso-Dominguez, Juan
Meeting Abstract. 10.1182/blood-2022-163016. 2022
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.
Labrador, Jorge; (...); Montesinos, Pau
Article. 10.1002/cncr.35431. 2024
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
Boluda B; (...); Montesinos P
Article. 10.1080/10428194.2021.1938031. 2021
Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Pemmaraju, Naveen; (...); Daver, Naval
Meeting Abstract. 10.1182/blood-2021-146666. 2021
Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial
Mosquera Orgueira, Adrian; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-180710. 2023
EXTRACORPOREAL PHOTOPHERESIS IN GRAFT-VERSUS-HOST DISEASE.
Canto, Pedro Asensi; (...); Segui, Ines Gomez
Article. 10.1016/j.jtct.2023.07.001. 2023
Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.1002/jca.21901. 2021
Factors Associated With Survival in Secondary Acute Myeloid Leukemia in Colombia
Sossa, Claudia; (...); Marcela Cuervo, Diana
Meeting Abstract. 2023
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
Ribera JM; (...); Sancho JM
Article. 10.3324/haematol.2023.283342. 2024
Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Espanol De Trasplante y Terapia Celular (GETH-TC) Study
Fabbri, Nicole; (...); Mussetti, Alberto
Meeting Abstract. 10.1182/blood-2023-185721. 2023
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
Zeidan, Amer M.; (...); Santini, Valeria
Article. 10.1038/s41375-022-01724-9. 2022
First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).
Jabbour, Elias; (...); Ribera, Josep-Maria
Meeting Abstract. 2023
First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
Jabbour, Elias; (...); Ribera, Jose-Maria
Meeting Abstract. 2023
FITNESS ASSESSMENT IN ACUTE MYELOID LEUKEMIA: RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF EUROPEAN LEUKEMIA NET.
Venditti, Adriano; (...); Ossenkoppele, Gert J
Article. 10.1182/bloodadvances.2024013744. 2025
Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.
Perl, Alexander E.; (...); Levis, Mark J.
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7013. 2021
Follow-up of Patients With FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukaemia in the Phase 3 ADMIRAL Trial
Perl, Alexander E.; (...); Levis, Mark J.
Meeting Abstract. 2022
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Perl AE; (...); Levis MJ
Article. 10.1182/blood.2021011583. 2022
Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
Bazarbachi, Ali; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2024-204672. 2024
FREQUENCY AND IMPACT OF SOMATIC MUTATIONS ON OUTCOMES OF ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY
Bazarbachi, Ali; (...); Mohty, Mohamad
Meeting Abstract. 2024
Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain.
Ribera, Josep-Maria; (...); Pinana, Jose-Luis
Article. 10.1016/j.clml.2021.06.024. 2021
Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.
Eirís J; (...); Sanz J
Article. 10.1016/j.jtct.2024.10.009. 2024
Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial
Pfeilstocker, M.; (...); Dombret, H.
Meeting Abstract. 2021
Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
D'Amico, Saverio; (...); Della Porta, Matteo Giovanni
Meeting Abstract. 10.1182/blood-2024-209541. 2024
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)
Lin, Wei-Yu; (...); Allan, James M.
Article. 10.1038/s41467-021-27679-6. 2022
GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS
Acha, P.; (...); Sole, F.
Meeting Abstract. 10.1016/j.leukres.2023.107253. 2023
GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
Bernard, E.; (...); Papaemmanuil, E.
Meeting Abstract. 10.1016/j.leukres.2023.107146. 2023
Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.
Gonzalez-Gil, Celia; (...); Genesca, Eulalia
Article. 10.3324/haematol.2022.281196. 2023
Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasms.
Torres-Esquius S; (...); Jerez A
Article. 10.1111/bjh.19460. 2024
Germline Predisposition in Myeloid Neoplasms Aged =50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making
Torres-Esquius, Sara; (...); Jerez, Andres
Meeting Abstract. 10.1182/blood-2023-179234. 2023
GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS
Santiago, M.; (...); Cervera-Zamora, J.
Meeting Abstract. 10.1016/j.leukres.2023.107247. 2023
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Sekeres MA; (...); Cortes JE
Article. 10.1038/s41375-023-02001-z. 2023
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial.
Roboz GJ; (...); Döhner H
Article. 10.1182/bloodadvances.2023012062. 2024
Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT.
Sanz, Jaime; (...); Ciceri, Fabio
Article. 10.1182/bloodadvances.2023012133. 2024
Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1097/HS9.0000000000000790. 2022
Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-144558. 2021
Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation
Sobas, Marta; (...); Maria Hernandez-Rivas, Jesus
Meeting Abstract. 10.1182/blood-2021-149521. 2021
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)
DiNardo, Courtney D.; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2021-147601. 2021
Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).
Dinardo, Courtney Denton; (...); De Botton, Stephane
Meeting Abstract. 2022
Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.
Dohner, Hartmut; (...); De Botton, Stephane
Meeting Abstract. 2022
Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Baron, Frederic; (...); Ciceri, Fabio
Article. 10.1002/ajh.27466. 2024
Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)
Salamero, Olga; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2021-152183. 2021
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.
Salamero, Olga; (...); Montesinos, Pau
Article. 10.1016/S2352-3026(24)00132-7. 2024
Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial.
Konopleva, Marina Y.; (...); Wei, Andrew H.
Article. 10.1182/bloodadvances.2021006303. 2022
Identification of Leukemia-Associated Immunophenotypes by Databaseguided Flow Cytometry Provides a Highly Sensitive and Reproducible Strategy for the Study of Measurable Residual Disease in Acute Myeloblastic Leukemia
Pinero, Paula; (...); Tarin, Fabian
Article. 10.3390/cancers14164010. 2022
Identifying prognostic gene panels in acute myeloid leukemia.
Sanchez-Garcia, Joaquin; (...); Montesinos, Pau
Article. 10.1080/17474086.2023.2193322. 2023
IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION
Eiris, Juan; (...); Balaguer-Rosello, Aitana
Meeting Abstract. 2024
Imaging features and clinical data-based network analysis of CAR-T treated B- cell lymphoma patients in relation to their TP53 mutation status
Estepa-Fernandez, A.; (...); Alberich-Bayarri, A.
Meeting Abstract. 2024
Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.
Article. 10.1007/s00277-024-05758-0. 2024
Immune Reconstitution Profiling Suggests Antiviral Protection After Transplantation with Omidubicel: a Phase 3 Substudy.
Szabolcs, Paul; (...); Horwitz, Mitchell E.
Article. 10.1016/j.jtct.2023.04.018. 2023
Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial
Schlenk, Richard F.; (...); Erba, Harry P.
Meeting Abstract. 2023
Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial
Schlenk, Richard F.; (...); Erba, Harry P.
Meeting Abstract. 10.1182/blood-2022-169011. 2022
IMPACT OF ALLO-HCT IN FIRST COMPLETE REMISSION (CR1) IN ADDITION TO FLT3 INHIBITION WITH QUIZARTINIB IN AML WITH FLT3-ITD: RESULTS FROM THE QUANTUM-FIRST TRIAL
Schlenk, Richard F.; (...); Erba, Harry P.
Meeting Abstract. 2023
IMPACT OF BUSULFAN, ETOPOSIDE AND HIGH-DOSE ARA-C (BEA) CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN AML
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 2023
Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols.
Barba P; (...); Ribera JM
Article. 10.1097/HS9.0000000000000810. 2023
IMPACT OF CYTOGENETIC ABNORMALITIES DEFINING AML MYELODYSPLASIA-RELATED (WHO AND ICC 2022) IN FIRST LINE DECITABINE IN UNFIT AML PATIENTS
de la Fuente, Adolfo; (...); Tormo, Mar
Meeting Abstract. 2023
Impact of Cytogenetic Risk on Outcomes of Non-T Cell Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1016/j.jtct.2022.08.018. 2022
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.
Ayala, Rosa; (...); Montesinos, Pau
Article. 10.3390/cancers14235799. 2022
Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study
Matteuzzi, Tommaso; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2021-152215. 2021
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1111/bjh.18765. 2023
Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Torrent, Anna; (...); Barba, Pere
Meeting Abstract. 10.1182/blood-2023-186388. 2023
IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
Marco-Ayala, Javier; (...); Solves, Pilar
Article. 10.1016/j.jtct.2023.01.009. 2023
Impact of SCHOLAR-1 criteria on CAR-T cell therapy efficacy in aggressive B lymphoma. A real-world GELTAMO/GETH study.
Oreiro MB; (...); García-Sancho AM
Article. 10.1016/j.jtct.2023.08.026. 2023
Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
Bastos-Oreiro, Mariana; (...); Martin Garcia-Sancho, Alejandro
Meeting Abstract. 10.1182/blood-2022-166329. 2022
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.
Kayser, Sabine; (...); Schlenk, Richard F.
Article. 10.3324/haematol.2022.282127. 2023
Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia
Marconi, Giovanni; (...); Martinelli, Giovanni
Meeting Abstract. 10.1182/blood-2023-184745. 2023
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Bernard, Elsa; (...); Elias, Harold K
Article. 10.1038/s41591-021-01367-w. 2021
Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil
de la Rubia, Javier; (...); Sanz, Miguel
Meeting Abstract. 2023
Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.
Castillo MI; (...); Díaz TM
Article. 10.1002/cam4.6300. 2023
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.3390/cancers15082267. 2023
Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
Sirenko, Maria; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2022-162397. 2022
Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
Asensi Cantó P; (...); Sanz J
Article. 10.1038/s41409-024-02391-3. 2024
Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2024.12.006. 2024
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Sobas, Marta; (...); Montesinos, Pau
Article. 10.1007/s00277-023-05582-y. 2023
In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph plus ALL.
Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.6533. 2024
In-depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph plus ALL
Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria
Meeting Abstract. 10.1016/S2152-2650(24)00426-9. 2024
Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
Labrador, Jorge; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-162591. 2022
Influence of Polymorphisms Related to Drug Metabolism in Allogeneic Bone Marrow Transplantation
Santiago, M; (...); Alino, S
Meeting Abstract. 2021
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.
Simoes C; (...); Paiva B
Article. 10.1182/bloodadvances.2022008141. 2023
Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309
Im, Annie; (...); Pavletic, Steven Z.
Meeting Abstract. 10.1182/blood-2022-169605. 2022
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
Montesinos, Pau; (...); Dohner, Hartmut
Article. 10.1056/NEJMoa2117344. 2022
Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.
Montesinos, Pau, de Botton, Stephane, Dohner, Hartmut
Letter. 10.1056/NEJMc2206489. 2022
Ivosidenib plus Azacitidine vs Placebo plus Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study
de Botton, Stephane; (...); Doehner, Hartmut
Meeting Abstract. 2023
Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First
Montesinos, Pau; (...); Dombret, Herve
Meeting Abstract. 10.1182/blood-2023-187286. 2023
ladademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial
Salamero, Olga; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-168945. 2022
LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors.
Cruz, David; (...); Gallardo, David
Article. 10.3389/fimmu.2023.1066393. 2023
Live donor kidney transplantation. Situation analysis and roadmap.
de la Oliva Valentín M; (...); Domínguez-Gil B
Article. 10.1016/j.nefroe.2022.02.002. 2022
Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.
Sanz, Miguel Angel; (...); Sanz, Jaime
Article. 10.1038/s41409-024-02319-x. 2024
Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.
Gomez, E; (...); Fernandez-Rodriguez, C M
Article. 10.1111/apt.18004. 2024
Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02012-5. 2023
Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2022-156231. 2022
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.
Recher, Christian; (...); Montesinos, Pau
Article. 10.1038/s41375-021-01425-9. 2022
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.
Wei, Andrew H.; (...); Roboz, Gail J.
Letter. 10.1002/ajh.26847. 2023
Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation
de Koning, Coco; (...); Nierkens, Stefan
Article. 10.1038/s41409-021-01417-4. 2021
LYMPHOPENIA IS HIGHLY PREVALENT IN MDS AND PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR IPSS-R VERY-LOW AND LOW-RISK PATIENTS. AN ANALYSIS FROM THE EU-MDS REGISTRY
Silzle, T.; (...); Smith, A.
Meeting Abstract. 2021
Lymphopenia is highly prevalent in MDS and provides prognostic information for IPSS-R (very)-low-risk patients. An analysis from the EU-MDS registry
Silzle, T.; (...); Smith, A.
Meeting Abstract. 2021
Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-167138. 2022
Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2023-183029. 2023
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
Zeidner, Joshua F; (...); Vyas, Paresh
Article. 10.1182/blood.2024027408. 2025
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
Onida F; (...); Pleyer L
Article. 10.1182/blood.2023023476. 2024
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
Ravandi, F; (...); Dombret, H
Article. 10.1186/s13045-021-01142-x. 2021
Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset
Bowen, David; (...); de Witte, Theo M.
Meeting Abstract. 10.1182/blood-2021-150322. 2021
Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases
Smoljanovic, Inga Mandac; (...); Bowen, David
Meeting Abstract. 10.1182/blood-2022-167716. 2022
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.
Buske C; (...); Passamonti F
Article. 10.1016/j.esmoop.2022.100403. 2022
MATCHED RELATED VERSUS MATCHED UNRELATED VERSUS HAPLOIDENTICAL DONORS IN FLT3-ITD + AML PATIENTS IN CR1: A STUDY FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY
Brissot, Eolia; (...); Ciceri, Fabio
Meeting Abstract. 2024
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial
Sierra, Jorge; (...); Venditti, Adriano
Article. 10.1182/bloodadvances.2023009847. 2023
Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones
Alfonso Pierola, Ana; (...); Prosper, Felipe
Meeting Abstract. 10.1182/blood-2023-188865. 2023
Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT
Baron, Frederic; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-186293. 2023
MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL
Gonzalez-Romero, E.; (...); Cervera-Zamora, J.
Meeting Abstract. 2021
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Sirenko, Maria; (...); Papaemmanuil, Elli
Article. 10.1182/blood.2023023723. 2024
Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH(1) Acute Myeloid Leukemia
De Botton, Stephane; (...); Fenaux, Pierre
Meeting Abstract. 10.1182/blood-2021-144912. 2021
Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo plus AZA in the AGILE Study
Doehner, Hartmut; (...); De Botton, Stephane
Meeting Abstract. 10.1182/blood-2022-159473. 2022
Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.
De Botton, Stephane; (...); Dohner, Hartmut
Meeting Abstract. 2022
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
Sargas, Claudia; (...); On Behalf Of Pethema Group
Article. 10.3390/cancers15020438. 2023
Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications
Bernard, Elsa; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2023-186863. 2023
Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications.
Bernard, Elsa; (...); Papaemmanuil, Elli
Article. 10.1182/blood.2023023727. 2024
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
Lin, Chenyu; (...); Horwitz, Mitchell E.
Article. 10.1016/j.jtct.2023.01.031. 2023
Multimodal analysis identifies microbiome changes linked to stem cell transplantation-associated diseases
Artacho, Alejandro; (...); Ubeda, Carles
Article. 10.1186/s40168-024-01948-0. 2024
MULTINATIONAL STUDY ASSESSING TREATMENT PATTERNS, OUTCOMES, AND HEALTHCARE RESOURCE UTILIZATION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH REFRACTORY/RESISTANT CYTOMEGALOVIRUS INFECTION, OR INTOLERANCE TO ANTI-CYTOMEGALOVIRUS THERAPIES
Papanicolaou, Genovefa; (...); Hirji, Ishan
Meeting Abstract. 2023
Multiomics Characterization of Normal CD34+Hematopoietic Progenitor Cells (HPC) and Blasts in the Bone Marrow (BM) and Peripheral Blood (PB) of Patients with Acute Myeloid Leukemia (AML)
Simoes, Catia; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-185760. 2023
Multiple phenotypes and epigenetic profiles in a three-generation family history with GATA2 deficiency.
Romero-Moya, Damia; (...); Giorgetti, Alessandra
Article. 10.1038/s41375-025-02519-4. 2025
Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia
Fabiani E; (...); Voso MT
Article. 10.1002/cam4.3904. 2021
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
Martin, I; (...); Tormo, M
Article. 10.1111/bjh.17675. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project.
Sargas C; (...); Montesinos P
Article. 10.3324/haematol.2020.263806. 2021
NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS
Balaguer Rosello, Aitana; (...); Sanz, Jaime
Meeting Abstract. 2023
New Cases and Mutations in SEC23B Gene Causing Congenital Dyserythropoietic Anemia Type II.
Musri, Melina Mara; (...); Sanchez, Mayka
Article. 10.3390/ijms24129935. 2023
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Castano-Bonilla, Tamara; (...); Montesinos, Pau
Article. 10.1155/2022/3132941. 2022
Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-021-01537-x. 2022
Non-T Depleted Haploidentical Stem Cell Transplantation in Aml Patients Achieving First Complete Remission After One Vs Two Induction Courses: A Study From The ALWP/EBMT
Nagler, A; (...); Mohty, M
Meeting Abstract. 2021
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1186/s13045-023-01450-4. 2023
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT (16, 58, 2023)
Nagler, Arnon; (...); Mohty, Mohamad
Correction. 10.1186/s13045-023-01501-w. 2023
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Cabrero M; (...); Caballero D
Article. 10.1038/s41409-023-02171-5. 2024
OLD MATCHED SIBLING DONOR VERSUS YOUNG HAPLOIDENTICAL DONOR FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA TRANSPLANTED IN FIRST REMISSION
Poire, Xavier; (...); Ciceri, Fabio
Meeting Abstract. 2024
Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide.
Piemontese S; (...); Ciceri F
Article. 10.1038/s41375-024-02359-8. 2024
Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia
Cortes, Jorge E.; (...); Wei, Andrew H.
Meeting Abstract. 10.1182/blood-2021-144905. 2021
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
de Botton, Stephane; (...); Cortes, Jorge
Article. 10.1182/bloodadvances.2022009411. 2023
Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial
Cortes, Jorge E.; (...); De Botton, Stephane
Meeting Abstract. 10.1182/blood-2022-167330. 2022
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts, Justin M.; (...); Cortes, Jorge E.
Article. 10.1016/S2352-3026(22)00292-7. 2022
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
Cortes, Jorge E.; (...); Olutasidenib Combination Therapy Study Grp
Article. 10.1186/s13045-024-01657-z. 2025
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
Cortes J; (...); Watts JM
Article. 10.1080/10428194.2024.2333451. 2024
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
Horwitz, ME; (...); Sanz, G
Article. 10.1182/blood.2021011719. 2021
Oral Azacitidine (Oral-AZA) improves Overall Survival (OS) and Relapse-free Survival (RFS) for patients with Acute Myeloid Leukemia (AML) in first remission after Intensive Chemotherapy (IC), regardless of amount of consolidation received: Results of the QUAZAR AML-001 maintenance trial
Dohner, H.; (...); Ravandi, F.
Meeting Abstract. 2021
Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukaemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial
Wei, Andrew; (...); Roboz, Gail
Meeting Abstract. 2022
Outcome of Allogeneic Stem Cell Transplantation in FLT3-TKD-Mutated AML - a Study on Behalf of the Acute Leukemia Working Party of the EBMT
Heinicke, Thomas; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-174233. 2023
Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy.
Perez, Ariadna; (...); Pinana, Jose Luis
Article. 10.1007/s15010-024-02213-0. 2024
Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020)
Kayser, Sabine; (...); Montesinos, Pau
Correction. 10.1038/s41375-021-01358-3. 2021
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
Martinez-Cuadron, David; (...); Montesinos, Pau
Article. 10.3324/haematol.2022.282506. 2024
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.
Caballero, Juan Carlos; (...); Diez Campelo, Maria
Article. 10.1177/20406207231218157. 2024
Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials
Ribera, JM; (...); PETHEMA Grp
Article. 10.1002/hon.2910. 2021
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
Socie, Gerard; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02127-9. 2024
Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial
DiNardo, Courtney D.; (...); de Botton, Stephane
Meeting Abstract. 10.1182/blood-2021-147593. 2021
Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis
Venditti, Adriano; (...); Pullarkat, Vinod
Meeting Abstract. 10.1182/blood-2023-182045. 2023
OUTCOMES OF CAR-T CELL THERAPY FOR LARGE B CELL LYMPHOMA IN PATIENTS OF 70 YEARS AND OLDER: MULTICENTRIC REAL WORLD EXPERIENCE
Bailen, Rebeca; (...); Barba, Pere
Meeting Abstract. 2023
Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT.
Baron F; (...); Mohty M
Article. 10.1038/s41409-023-02000-9. 2023
Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.
Rafii, Hanadi; (...); Gluckman, Eliane
Article. 10.1182/bloodadvances.2022007941. 2022
Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
Ibanez, Mariam; (...); Luna I
Article. 10.3390/diagnostics12040953. 2022
PAN-STAKEHOLDER CORE OUTCOME SET (COS) DEFINITION FOR HEMATOLOGICAL MALIGNANCIES IN THE FRAMEWORK OF THE EU PROJECT, HARMONY: THE HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINE OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY
Lang, K.; (...); Bullinger, L.
Meeting Abstract. 2023
Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
Lang, Katharina M.; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-157549. 2022
Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance
Lang, Katharina M.; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2021-145002. 2021
Patient Reported Outcomes in Patients with Newly Diagnosed FLT3(mut+) acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Lacewing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone
Wang, Eunice S.; (...); Shah, Manasee V.
Meeting Abstract. 10.1182/blood-2021-144977. 2021
Patient-reported Outcomes in Adults With Newly Diagnosed Ph plus Acute Lymphoblastic Leukemia Treated With Ponatinib or Imatinib in Combination With Reduced-Intensity Chemotherapy: Results From the Phase III PhALLCON Study
Ashaye, Ajibade; (...); Guo, Shien
Meeting Abstract. 2024
PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines.
González-Romero E; (...); Vázquez-Manrique RP
Article. 10.3390/cancers15174263. 2023
Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
Sargas, Claudia; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-166639. 2022
Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
Walker, Alison R.; (...); William Burke, Patrick
Meeting Abstract. 2022
Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: The DIAMOND-01 trial.
Martinelli, Giovanni; (...); Montesinos, Pau
Meeting Abstract. 2022
Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy.
Wang, Eunice S.; (...); Tiu, V, Ramon
Article. 10.1182/blood.2021014586. 2022
Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy
Wang, Eunice S.; (...); Tiu, Ramon V.
Meeting Abstract. 10.1182/blood-2021-145379. 2021
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Roboz, Gail J.; (...); Wei, Andrew H.
Letter. 10.1080/10428194.2021.2012667. 2022
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Daver NG; (...); Kantarjian HM
Article. 10.1016/S1470-2045(23)00674-5. 2024
Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia
Daver, Naval; (...); Sweet, Kendra
Meeting Abstract. 10.1182/blood-2023-173413. 2023
Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results.
Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon
Article. 10.1002/hem3.67. 2024
PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIC CHROMOSOME (LAL PH plus ). RESULTS OF THE PONALFIL CLINICAL TRIAL WITH MEDIUM 2-YEAR FOLLOW-UP
Ribera Santasusana, J. M.; (...); Garcia-Sanz, R.
Meeting Abstract. 2021
Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph plus ALL: Subgroup Analysis of the Phase 3 Phallcon Study
Aldoss, Ibrahim; (...); Jabbour, Elias
Meeting Abstract. 10.1182/blood-2023-179537. 2023
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Jabbour, Elias; (...); Ribera, Jose-Maria
Article. 10.1001/jama.2024.4783. 2024
Ponatinib, Chemotherapy, and Transplant in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon
Article. 10.1182/bloodadvances.2022007764. 2022
POOLED FECAL ALLOGENEIC MICROBIOTHERAPY FOR REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUSHOST DISEASE: RESULTS FROM THE EARLY ACCESS PROGRAM IN EUROPE
Malard, Florent; (...); Mohty, Mohamad
Meeting Abstract. 2024
POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) VERSUS ANTI-THYMOCYTE GLOBULIN (ATG) VERSUS COMBINATION FOR GRAFT-VERSUS-HOST DISEASE PREVENTION IN HAPLOIDENTICAL TRANSPLANTATION FOR ADULT ACUTE MYELOID LEUKEMIA: A REPORT FROM THE EBMT
Bazarbachi, Abdul-Hamid; (...); Mohty, Mohamad
Meeting Abstract. 2023
Post-transplant cyclophosphamide after HLA identical compared to Haploidentical donor transplant in Acute Myeloid Leukemia: a study on behalf of GETH-TC.
Bailen, Rebeca; (...); Kwon, Mi
Article. 10.1016/j.jtct.2022.01.020. 2022
Post-Transplant Cyclophosphamide after HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of Geth-TC
Bailen, Rebeca; (...); Kwon, Mi
Meeting Abstract. 10.1182/blood-2021-150835. 2021
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari, Lorenzo; (...); Sanz, Jaime
Article. 10.1038/s41409-022-01725-3. 2022
Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT
Sanz, J; (...); Mohty, M
Article. 10.1186/s13045-021-01094-2. 2021
Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT.
Wieczorek, Michele; (...); Mohty, Mohamad
Letter. 10.1002/ajh.26782. 2022
Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT
Wieczorek, Michele; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-151087. 2021
Post-transplant cyclophosphamide separates graft-versus host disease (GVHD) and graft versus leukemia (gvl) effects after HLA- matched stem-cell transplantation (sct) for AML
Shimoni, A.; (...); Mohty, M.
Meeting Abstract. 2022
Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
Battipaglia, Giorgia; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2024-207391. 2024
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel, Sebastian; (...); Mohty, Mohamad
Article. 10.1002/cncr.35004. 2023
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with all treated in CR1 with allo-HCT from matched unrelated donors. A study from ALWP of the EBMT
Giebel, S.; (...); Mohty, M.
Meeting Abstract. 2022
Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.
Bazarbachi, Abdul-Hamid; (...); Mohty, Mohamad
Article. 10.1002/cncr.35365. 2024
Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi, Firoozeh; (...); Schonland, Stefan
Article. 10.1016/j.jtct.2021.09.008. 2021
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Montoro, Juan; (...); Glass, Bertram
Article. 10.1016/j.jtct.2023.11.021. 2024
Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party
Abou Dalle, Iman; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-187095. 2023
Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model
Ferrer-Lores, Blanca; (...); Alberich-Bayarri, Angel
Article. 10.1186/s13550-024-01172-9. 2024
Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
Shortt, Jake; (...); Wei, Andrew H.
Meeting Abstract. 10.1182/blood-2022-166937. 2022
Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party
Bazarbachi, Ali; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-182823. 2023
Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation
Caballero, Teresa; (...); Perez-Simon, Jose A.
Meeting Abstract. 10.1182/blood-2021-151533. 2021
PROGNOSIS VALUE OF MINIMAL DETECTABLE DISEASE (MDD) BY 2(nd) GENERATION ALLOGENIC PRE-TRANSPLANTATION CYTOMETRY IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA
Velazquez Teresa, Caballero; (...); Jose Antonio, Perez Simon
Meeting Abstract. 2021
Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).
Roboz, Gail J.; (...); Dohner, Hartmut
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7014. 2021
Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance
Dohner, Hartmut; (...); de Menezes, Daniel Lopes
Meeting Abstract. 10.1182/blood-2021-147465. 2021
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Dohner, Hartmut; (...); Lopes de Menezes D
Article. 10.1182/blood.2022016293. 2022
Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
Uriel Suarez, Edwin; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-167365. 2022
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Castaño-Bonilla T; (...); Montesinos, P
Article. 10.1038/s41598-021-00050-x. 2021
Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.
Caballero-Velazquez, Teresa; (...); Perez-Simon, Jose A.
Article. 10.3390/cancers15051609. 2023
PROPOSED MOLECULAR CLASSIFICATION OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BASED ON SPLICING EVENTS
Liquori, A.; (...); Cervera Zamora, J.
Meeting Abstract. 2021
PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT.
Montoro J; (...); Glass B
Article. 10.1182/bloodadvances.2024013328. 2024
QuANTUM-First Trial: FLT3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS)
Levis, Mark J.; (...); Perl, Alexander E.
Meeting Abstract. 2023
Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival
Levis, Mark J.; (...); Perl, Alexander
Meeting Abstract. 10.1182/blood-2022-162739. 2022
Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction ( IND) and Consolidation CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3-ITD+ AML Patients (pts)
Perl, Alexander; (...); Levis, Mark J.
Meeting Abstract. 10.1182/blood-2023-186785. 2023
QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients
Perl, Alexander E.; (...); Levis, Mark J.
Meeting Abstract. 2024
QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
Erba, Harry P.; (...); Montesinos, Pau
Meeting Abstract. 2024
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba, Harry P.; (...); Schlenk, Richard F.
Article. 10.1016/S0140-6736(23)00464-6. 2023
Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML
Schlenk, R.; (...); Erba, H.
Meeting Abstract. 2022
Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/ Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis
Garcia-Manero, Guillermo; (...); Yacoub, Abdulraheem
Meeting Abstract. 2023
RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
Garcia-Manero, G.; (...); Yacoub, A.
Meeting Abstract. 10.1016/j.leukres.2023.107270. 2023
REAL-LIFE EVIDENCE OF VENETOCLAX TREATMENT IN PATIENTS WITH ACUTE REPLAPSE OR REFRACTORY LEUKEMIA MYELOID
Jorge, Labrador; (...); Pau, Montesinos
Meeting Abstract. 2021
Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.
Asensi Cantó P; (...); Gómez-Seguí I
Article. 10.1016/j.jtct.2023.09.001. 2023
Real-world experience with CPX-351 in high-risk acute myeloid leukemia.
Lemoli, Roberto M., Montesinos, Pau, Jain, Akriti
Article. 10.1016/j.critrevonc.2023.103984. 2023
Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged = 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia
Requena, Gaspar Aspas; (...); Matinez-Cuadron, David
Meeting Abstract. 10.1182/blood-2023-190128. 2023
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
Sauta, Elisabetta; (...); Della Porta, Matteo G.
Meeting Abstract. 10.1182/blood-2022-163634. 2022
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta, Elisabetta; (...); Della Porta, Matteo Giovanni
Article. 10.1200/JCO.22.01784. 2023
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
Hernandez-Sanchez, Alberto; (...); Bullinger, Lars
Article. 10.1038/s41375-024-02333-4. 2024
Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database
Hernandez Sanchez, Alberto; (...); Bullinger, Lars
Meeting Abstract. 10.1182/blood-2022-167480. 2022
Recent advances in allogeneic transplantation for acute myeloid leukemia.
Montoro J, Balaguer-Roselló A, Sanz J
Article. 10.1097/CCO.0000000000000992. 2023
Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.07.008. 2023
Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype.
Mallo, Mar; (...); Sole, Francesc
Article. 10.1002/jha2.651. 2023
Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2.
Montesinos, Pau; (...); Heuser, Michael
Article. 10.3390/cancers16101824. 2024
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria*
Triguero, A.; (...); Sanz, G.
Article. 10.1016/j.leukres.2022.106836. 2022
Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)
Roboz, Gail J.; (...); Dohner, Hartmut
Meeting Abstract. 10.1182/blood-2021-147769. 2021
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)
Kantarjian, Hagop M.; (...); Chiao, Judy H.
Article. 10.1002/cncr.33828. 2021
RESULTS OF HLA IDENTICAL ALLOGENIC TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS HAPLOIDENTIAL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: EXPERIENCE OF THE SPANISH HAEMATOPOIETIC TRANSPLANT GROUP (GETH)
Almorox Rebeca, Bailen; (...); Mi, Kwon
Meeting Abstract. 2021
Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.
Torrent, Anna; (...); Ribera, Josep-Maria
Article. 10.1111/ejh.14031. 2023
Revisiting Co-existing Chromosomal Abnormalities in NPM1-mutated AML in Light of the Revised ELN 2022 classification.
Angenendt, Linus; (...); Schliemann, Christoph
Article. 10.1182/blood.2022018582. 2022
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Mussetti, Alberto; (...); Sureda, Anna
Article. 10.1038/s41409-023-01949-x. 2023
Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era
Mussetti, Alberto; (...); Sureda, Anna
Meeting Abstract. 10.1182/blood-2022-160000. 2022
Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia
Ribera, Jordi; (...); Ribera, Josep-Maria
Meeting Abstract. 10.1182/blood-2023-186265. 2023
Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.
Pinto-Merino, Alvaro; (...); Saiz-Rodriguez, Miriam
Article. 10.3390/pharmaceutics14030559. 2022
Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program
Zeidan, Amer M.; (...); Garcia-Manero, Guillermo
Meeting Abstract. 10.1182/blood-2021-145626. 2021
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
Daver, Naval; (...); Sweet, Kendra
Meeting Abstract. 10.1182/blood-2021-146503. 2021
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups
Vives, Susana; (...); PETHEMA Grp
Article. 10.3390/cancers16234028. 2024
Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using PostTransplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-180075. 2023
SECOND ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT2) FOR PRIMARY GRAFT FAILURE IN PATIENTS WITH ACUTE LEUKEMIA IN REMISSION: ON BEHALF OF THE ALWP OF THE EBMT
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 2023
Secondary Acute Myeloid Leukemia from a Previous Chronic Myeloproliferative Neoplasm: A Study of Grelam-Chile Concerning Chilean Patients on Behalf of AML Pethema Registry
Espinoza, Marcela; (...); Martinez-Cuadron, David
Meeting Abstract. 10.1182/blood-2023-185288. 2023
Secondary neoplasms after umbilical cord blood transplantation. On behalf of eurocord and the european group for blood and marrow transplantation
El Ayoubi, H. Rafii; (...); Gluckman, E.
Meeting Abstract. 2022
SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial
Paoli, Alessandro; (...); Pellacani, Andrea
Meeting Abstract. 10.1182/blood-2021-150277. 2021
Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT.
Kharfan-Dabaja, Mohamed A.; (...); Mohty, Mohamad
Article. 10.1097/HS9.0000000000000920. 2023
Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial
Torrent, Anna; (...); Ribera, Josep-Maria
Meeting Abstract. 10.1182/blood-2024-207954. 2024
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
Risueno, Alberto; (...); Hasan, Maroof
Article. 10.1016/j.leukres.2024.107497. 2024
Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with ß-thalassemia.
Bardón-Cancho EJ; (...); Cela E
Article. 10.1007/s00277-024-05694-z. 2024
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
Shallis RM; (...); Zeidan AM
Article. 10.1016/S2352-3026(23)00159-X. 2023
Starkeya nomas sp. nov., a prosthecate and budding bacterium isolated from an immunocompromized patient.
Sahuquillo-Arce JM; (...); López-Hontangas JL
Article. 10.1099/ijsem.0.005805. 2023
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)+azacitidine in higher risk MDS and CMML-2.
Zeidan AM; (...); Santini V
Article. 10.2217/fon-2022-1237. 2023
Survival of Patients with Acute Myeloid Leukemia According to Age in a University Hospital in Colombia
Melo, CLS; (...); Montesinos, P
Meeting Abstract. 2021
Survival of Patients with Acute Myeloid Leukemia, Taken to Hematopoietic Stem Cell Transplantation: Experience of A Center in Colombia
Melo, CLS; (...); Ortiz, MF
Meeting Abstract. 2021
Survival of Patients with Secondary Acute Myeloid Leukemia in a University Hospital in Colombia
Ortiz, MF; (...); Sossa, C
Meeting Abstract. 2021
Survival Outcomes for Patients (pts) in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine (Oral-AZA) or Placebo (PBO)
Pfeilstoecker, M.; (...); Doehner, H.
Meeting Abstract. 2023
Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo
Ravandi, Farhad; (...); Doehner, Hartmut
Meeting Abstract. 10.1182/blood-2022-159045. 2022
Survival outcomes from the QUAZAR AML-001 trial with oral azacitidine (Oral-AZA) for patients with acute myeloid leukemia (AML) in remission by disease subtype, cytogenetic risk, and NPM1 mutation status at diagnosis (Dx)
Pfeilstoecker, Michael; (...); Menezes, Daniel
Meeting Abstract. 2022
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Ravandi, Farhad; (...); Roboz, Gail J
Article. 10.1111/bjh.19202. 2023
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase 3 QUAZAR AML-001 trial.
Wei AH; (...); Ravandi F
Article. 10.3324/haematol.2022.282296. 2023
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
T REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH SECONDARY VERSUS DE NOVO AML: A STUDY FROM THE ALWP /EBMT
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 2023
t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group
Ribera, J; (...); Ribera, JM
Meeting Abstract. 2021
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.
Martín-Sánchez E; (...); Zabaleta A
Article. 10.1182/bloodadvances.2024013212. 2024
TBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMT
Swoboda, R.; (...); Mohty, M.
Meeting Abstract. 2022
T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.01.016. 2023
The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency.
Santiago, Marta; (...); Cervera, Jose
Article. 10.3390/cancers15051590. 2023
THE COMBINATION OF GENOMIC ANALYSIS AND MINIMAL RESIDUAL DISEASE IMPROVES THE STRATIFICATION OF ADULT PATIENTS WITH TYPE T-LYMPHOBLASTIC LEUKEMIA (LAL-T) TREATED ACCORDING TO THE PETHEMA PROTOCOLS
Gonzalez Gil, C.; (...); Genesca Ferrer, E.
Meeting Abstract. 2021
The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe
Platzbecker, Uwe; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2021-145099. 2021
The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial
Mosquera Orgueira, Adrian; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-180482. 2023
The Impact of Cytogenetic Risk on Outcome of Non-T Cell Depleted Haploidentical Stem Cell Transplantation in Relapsed/Refractory AML: A Study From The ALWP/EBMT
Nagler, A; (...); Mohty, M
Meeting Abstract. 2021
The Impact of DNMT3A Mutation on Survival of AML Patients Receiving Allogeneic Hematopoietic Cell Transplantation in First Remission Depends on the Karyotype and CoOccurring Mutations: On Behalf of the EBMT Acute Leukemia Working Party
Dalle, Abou; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-179531. 2023
The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.
Kanda, Junya; (...); Gluckman, Eliane
Article. 10.1038/s41409-021-01479-4. 2022
The Impact of GVHD on Outcomes After Adult Single Cord Blood Transplantation In European And Japanese Populations: The EUROCORD/ALWP EBMT And JSHCT/JDCHCT Collaborative Study
Kanda, J; (...); Gluckman, E
Meeting Abstract. 2021
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
Ayala, R; (...); Montesinos, P
Article. 10.3390/cancers13102458. 2021
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.
Villar, Sara; (...); Montesinos, Pau
Article. 10.3389/fonc.2022.1054458. 2022
Thiotepa-based reduced-intensity conditioning are a valid alternative to total-body irradiation-based regimens in patients with acute lymphoblastic leukemia: A study of the alwp of the ebmt
Battipaglia, G.; (...); Mohty, M.
Meeting Abstract. 2022
Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Battipaglia, Giorgia; (...); Mohty, Mohamad
Article. 10.1016/j.jtct.2023.09.028. 2024
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
Jonas, Brian A.; (...); Ofran, Yishai
Article. 10.1002/ajh.26600. 2022
Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy
Benzaquen, Ana; (...); Solano, Carlos
Article. 10.1038/s41409-023-02114-0. 2024
TORQUE TENO VIRUS PLASMA DNA LOAD: A NOVEL PROGNOSTIC BIOMARKER IN CAR-T THERAPY
Hernani, Rafael; (...); Solano, Carlos
Meeting Abstract. 2023
Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.
Article. 10.1038/s41409-024-02298-z. 2024
Towarda more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).
Efficace, Fabio; (...); Zeidan, Amer M
Article. 10.1002/hem3.69. 2024
Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
Patricia Simoes, Catia; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163159. 2022
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Simoes, Catia; (...); Montesinos, Pau
Letter. 10.1111/bjh.18815. 2023
TRANSCRIPTIONAL CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA AT DIAGNOSIS IN THE ELDERLY PATIENT WITH IDENTIFICATION OF NEW PROGNOSTIC GROUPS
Sara, Villar; (...); Pau, Montesinos
Meeting Abstract. 2021
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.
Solves, Pilar; (...); Sanz, Jaime
Article. 10.3390/jcm12103467. 2023
Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry
Martinez-Cuadron, David; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2023-189800. 2023
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.
Lloret-Madrid, Pilar; (...); Montesinos, Pau
Article. 10.1002/cncr.35696. 2025
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1182/bloodadvances.2021005335. 2022
Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry
Diez-Campelo, Maria; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2021-146019. 2021
TRENDS IN THE USE OF HEMATOPOIETIC CELL TRANSPLANTATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
Giebel, Sebastian; (...); Ciceri, Fabio
Meeting Abstract. 10.1007/s00277-019-03771-2. 2024
UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes
Sirenko, Maria; (...); Papaemmanuil, Elli
Meeting Abstract. 10.1182/blood-2023-182949. 2023
UNRELATED DONOR SELECTION FOR STEM CELL TRANSPLANT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 2024
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.
Al Hamed, Rama; (...); Mohty, Mohamad
Article. 10.1002/cncr.34843. 2023
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Erba, Harry P.; (...); Wang, Eunice S.
Meeting Abstract. 10.1182/blood-2022-167412. 2022
Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.
De Botton, Stephane; (...); Dohner, Hartmut
Meeting Abstract. 2023
Updated efficacy and safety data from the AGILE study in patients with newly-diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine
Heuser, M.; (...); Doehner, H.
Meeting Abstract. 2023
Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.
Solomon, Scott R.; (...); Ravandi, Farhad
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7023. 2021
Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis.
Saiz-Rodriguez, M; (...); Montesinos, P
Article. 10.3390/cancers13225677. 2021
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14071734. 2022
VALIDATION OF FREQUENT SPLICING EVENTS IN ACUTE MYELOID LEUKEMIA WITH POTENTIAL TO GENERATE NEOANTIGENS
Beatriz, Fernandez-Blanco; (...); Jose Vicente, Cervera Zamora
Meeting Abstract. 2021
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
De la Torre EP; (...); Montesinos P
Letter. 10.3324/haematol.2023.284601. 2024
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
Pratz, Keith W.; (...); Fiedler, Walter
Article. 10.1038/s41408-022-00668-8. 2022
WHO and ICC 2022 Cytogenetic Abnormalities Defining Acute Myelogenous Leukemia (AML) Myelodysplasia-Related in First-Line Decitabine in Unfit AML Patients
Ortiz Lopez, Alicia; (...); de la Fuente Burguera, Adolfo
Meeting Abstract. 2023
Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT.
Sanz, Jaime; (...); Ciceri, Fabio
Article. 10.1182/blood.2023023697. 2024
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Wang ES; (...); Fathi AT
Article. 10.1016/S1470-2045(24)00386-3. 2024